Meritxell Sabidó
Research Subjects
Meritxell Sabidó has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Melinda Magyari
Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark
3 shared publications Anja Pinborg
Fertility Clinic, Department of Gynaecology, Fertility and Obstetrics, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark
2 shared publicationsDitte Vassard
Fertility Clinic, Department of Gynaecology, Fertility and Obstetrics, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark
2 shared publications- Elisabeth Framke
The Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark
2 shared publications Juan Enrique Schwarze
Merck Healthcare KGaA, Darmstadt, Germany
2 shared publications- Lene von Kappelgaard
The Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital – Rigshospitalet, Glostrup, Denmark
2 shared publications
Latest Publications
- Open Access
- 28 March 2026
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 19
Insights into adherence to cladribine tablets in the real world in multiple countries: results from patient support programs
Background: Patient support programs (PSP) help initiate and maintain disease-modifying treatment (DMT) for people with multiple sclerosis (PwMS). adveva ® (worldwide), Alcura Healthcare (Netherlands), and MS LifeLines ® (US) are nurse–pharmacy-led PSPs that collect clinical information, with consent, on PwMS receiving cladribine tablets (3.5 mg/kg over 2 years followed by a 2-year treatment-free period per product label). Objective: To evaluate initiation and completion of short courses of cladribine tablets treatment in Years 1 and 2 for PwMS and the frequency of subsequent treatment. Design: Retrospective, multinational, observational study using real-world data from PSPs. Methods: Clinical data from PSPs in Australia, Canada, Gulf, Latin America, Near East, Netherlands, UK, and US (December 2017–December 2023) included prior DMT use, cladribine tablets initiation and completion (Years 1 and 2), and subsequent treatment after Year 2 for those with ⩾48 months’ follow-up. Results: Across all PSPs, 22,082 PwMS initiated cladribine tablets (Australia, n = 799; Canada, n = 3665; Gulf, n = 258; Latin America, n = 1854; Near East, n = 86; Netherlands, n = 681; UK, n = 2320; US, n = 12,418), of whom 70.9%–81.3% were female (mean age 34.2–49.1 years). Most were DMT-experienced (Australia, no contribution to analysis; Canada, 100%; Gulf, 52.7%; Latin America, 57.7%; Near East, 86.0%; Netherlands, 81.4%; UK, 30.0%; US, 79.5%) with oral DMTs most commonly used (36.5%–69.3%). In PwMS with ⩾18 months’ follow-up, ⩾82.8% initiated Year 2 treatment at a mean of 12.4 (±3.8) to 13.9 (±3.5) months after initiating Year 1 treatment. Of those commencing Year 2 treatment, ⩾93.6% completed it. Additional treatment with cladribine tablets beyond 48 months was administered in a small proportion of PwMS: Canada, 5.6%; Latin America, 4.3%; Netherlands, 3.8%; and UK, 1.8%. Conclusion: Cladribine tablets adherence was high, with most PwMS completing short-course cladribine tablets treatment in Years 1 and 2. Of those with ⩾48 months’ follow-up, only a small proportion received additional cladribine tablets treatment.
- 28 March 2026
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 19
Open AccessInsights into adherence to cladribine tablets in the real world in multiple countries: results from patient support programs
Background: Patient support programs (PSP) help initiate and maintain disease-modifying treatment (DMT) for people with multiple sclerosis (PwMS). adveva ® (worldwide), Alcura Healthcare (Netherlands), and MS LifeLines ® (US) are nurse–pharmacy-led PSPs that collect clinical information, with consent, on PwMS receiving cladribine tablets (3.5 mg/kg over 2 years followed by a 2-year treatment-free period per product label). Objective: To evaluate initiation and completion of short courses of cladribine tablets treatment in Years 1 and 2 for PwMS and the frequency of subsequent treatment. Design: Retrospective, multinational, observational study using real-world data from PSPs. Methods: Clinical data from PSPs in Australia, Canada, Gulf, Latin America, Near East, Netherlands, UK, and US (December 2017–December 2023) included prior DMT use, cladribine tablets initiation and completion (Years 1 and 2), and subsequent treatment after Year 2 for those with ⩾48 months’ follow-up. Results: Across all PSPs, 22,082 PwMS initiated cladribine tablets (Australia, n = 799; Canada, n = 3665; Gulf, n = 258; Latin America, n = 1854; Near East, n = 86; Netherlands, n = 681; UK, n = 2320; US, n = 12,418), of whom 70.9%–81.3% were female (mean age 34.2–49.1 years). Most were DMT-experienced (Australia, no contribution to analysis; Canada, 100%; Gulf, 52.7%; Latin America, 57.7%; Near East, 86.0%; Netherlands, 81.4%; UK, 30.0%; US, 79.5%) with oral DMTs most commonly used (36.5%–69.3%). In PwMS with ⩾18 months’ follow-up, ⩾82.8% initiated Year 2 treatment at a mean of 12.4 (±3.8) to 13.9 (±3.5) months after initiating Year 1 treatment. Of those commencing Year 2 treatment, ⩾93.6% completed it. Additional treatment with cladribine tablets beyond 48 months was administered in a small proportion of PwMS: Canada, 5.6%; Latin America, 4.3%; Netherlands, 3.8%; and UK, 1.8%. Conclusion: Cladribine tablets adherence was high, with most PwMS completing short-course cladribine tablets treatment in Years 1 and 2. Of those with ⩾48 months’ follow-up, only a small proportion received additional cladribine tablets treatment.
- Open Access
- 11 February 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (2) , e70296
Evaluating Data Quality by Proxy: Can We Evaluate All Dimensions of the European Medicines Agency Data Quality Framework for Registry‐Based Post‐Authorization Safety Studies?
Purpose: An increasing number of studies based on secondary data use, including registry‐based studies, have been initiated to address post‐authorization regulatory commitments. We map differences across tools used in data quality (DQ) assessments, including those embedded in fitness‐for‐purpose (FFP) assessments, and describe their strengths and limitations for use in DQ assessments of registries considered for use in post‐approval safety studies (PASS). We focus on the use case where marketing authorization holders (MAHs) cannot directly analyze patient‐level data. Furthermore, we propose complementary measures to improve DQ assessment, including a set of data quality indicators (DQIs). Methods: We analyzed the extent to which the selected tools used in registry assessments address DQ dimensions and metrics defined in the European Medicines Agency‐DQ Framework (EMA‐DQF). We specifically considered the use case where DQ assessment was purely based on registry documentation and qualitative due to data access restrictions. Results: None of the tools covered all DQ dimensions and metrics; they had limited utility for evaluating extensiveness (i.e., completeness and coverage), semantic coherence, and reliability (i.e., accuracy and plausibility). Furthermore, some supporting document requirements were more useful than others. For example, the data dictionary is useful for evaluating precision and structural coherence. In contrast, publications have limited utility in DQ assessment. Conclusions: We propose a set of consistent definitions of information requirements and quantitative DQIs that complement existing tools that can be used for evaluating DQ throughout the registry‐based PASS lifecycle. If DQIs cannot be evaluated during the preparation of the PASS protocol, uncertainties and their potential impact on the study results need to be acknowledged in the relevant study documents. Additionally, scenario mapping for the removal or replacement of registries with insufficient DQ after PASS initiation is needed.
- 11 February 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (2) , e70296
Open AccessEvaluating Data Quality by Proxy: Can We Evaluate All Dimensions of the European Medicines Agency Data Quality Framework for Registry‐Based Post‐Authorization Safety Studies?
Purpose: An increasing number of studies based on secondary data use, including registry‐based studies, have been initiated to address post‐authorization regulatory commitments. We map differences across tools used in data quality (DQ) assessments, including those embedded in fitness‐for‐purpose (FFP) assessments, and describe their strengths and limitations for use in DQ assessments of registries considered for use in post‐approval safety studies (PASS). We focus on the use case where marketing authorization holders (MAHs) cannot directly analyze patient‐level data. Furthermore, we propose complementary measures to improve DQ assessment, including a set of data quality indicators (DQIs). Methods: We analyzed the extent to which the selected tools used in registry assessments address DQ dimensions and metrics defined in the European Medicines Agency‐DQ Framework (EMA‐DQF). We specifically considered the use case where DQ assessment was purely based on registry documentation and qualitative due to data access restrictions. Results: None of the tools covered all DQ dimensions and metrics; they had limited utility for evaluating extensiveness (i.e., completeness and coverage), semantic coherence, and reliability (i.e., accuracy and plausibility). Furthermore, some supporting document requirements were more useful than others. For example, the data dictionary is useful for evaluating precision and structural coherence. In contrast, publications have limited utility in DQ assessment. Conclusions: We propose a set of consistent definitions of information requirements and quantitative DQIs that complement existing tools that can be used for evaluating DQ throughout the registry‐based PASS lifecycle. If DQIs cannot be evaluated during the preparation of the PASS protocol, uncertainties and their potential impact on the study results need to be acknowledged in the relevant study documents. Additionally, scenario mapping for the removal or replacement of registries with insufficient DQ after PASS initiation is needed.
- Open Access
- 10 January 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (2) , 475-478
Summary of Research: Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the Global MAPLE-MS Pharmacovigilance Program
Information on pregnancy and infant outcomes after cladribine tablets exposure is limited, as its use is not recommended during pregnancy. This is a summary of the original published article ‘Pregnancy and infant outcomes in multiple sclerosis: findings from the Global MAPLE-MS Pharmacovigilance Program’. The primary outcome is the prevalence of major congenital anomalies (MCAs) in babies. Secondary outcomes include other pregnancy outcomes (live birth, elective termination, spontaneous abortion, ectopic pregnancy, and stillbirth).
- 10 January 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (2) , 475-478
Open AccessSummary of Research: Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the Global MAPLE-MS Pharmacovigilance Program
Information on pregnancy and infant outcomes after cladribine tablets exposure is limited, as its use is not recommended during pregnancy. This is a summary of the original published article ‘Pregnancy and infant outcomes in multiple sclerosis: findings from the Global MAPLE-MS Pharmacovigilance Program’. The primary outcome is the prevalence of major congenital anomalies (MCAs) in babies. Secondary outcomes include other pregnancy outcomes (live birth, elective termination, spontaneous abortion, ectopic pregnancy, and stillbirth).
- Open Access
- 20 October 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (1) , 44-49
Relapse activity after assisted reproductive technology treatments in women with multiple sclerosis: a nationwide cohort study in Denmark
Background Evidence on relapse activity in relapsing-remitting multiple sclerosis (RRMS) after assisted reproductive technology (ART) treatment differs. We investigated whether relapse activity increased after ART initiation. Methods Women with RRMS from the Danish MS Registry who underwent ART treatment from 1995 to 2018 were eligible. The annualised relapse rate (ARR) and corresponding 95% CI at 3 and 9 months post-ART initiation versus 12 months pre-ART were investigated using a negative binomial regression model. Analyses were stratified for live births within 12 months post-ART and disease-modifying therapy (DMT) use pre-ART. Clinical and demographic factors associated with relapse risk were identified. Results At ART initiation, 162 women, median age 33 years (IQR: 30–37), median Expanded Disability Status Scale score 1.5 (IQR: 1.0–2.5) were included; 55 (34.0%) were exposed to DMT. 27 relapses were recorded (ARR (95% CI) 0.17 (0.11 to 0.26)) at 12 months pre-ART; 7 relapses and 0.17 (0.08 to 0.36) at 3 months post-ART initiation, and 16 relapses and 0.13 (0.08 to 0.23) at 9 months post-ART initiation. When stratified by ART outcomes, relapse counts in subgroups became small. Women continuing DMT at ART initiation showed a statistically non-significant increase in ARR at 3 months post-ART. Conclusions Women with RRMS in Denmark did not, on average, have increased relapse activity at 3 and 9 months post-ART initiation compared with 12 months pre-ART. Women with disease activity pre-ART initiation may have a potentially elevated relapse risk post-ART.
- 20 October 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (1) , 44-49
Open AccessRelapse activity after assisted reproductive technology treatments in women with multiple sclerosis: a nationwide cohort study in Denmark
Background Evidence on relapse activity in relapsing-remitting multiple sclerosis (RRMS) after assisted reproductive technology (ART) treatment differs. We investigated whether relapse activity increased after ART initiation. Methods Women with RRMS from the Danish MS Registry who underwent ART treatment from 1995 to 2018 were eligible. The annualised relapse rate (ARR) and corresponding 95% CI at 3 and 9 months post-ART initiation versus 12 months pre-ART were investigated using a negative binomial regression model. Analyses were stratified for live births within 12 months post-ART and disease-modifying therapy (DMT) use pre-ART. Clinical and demographic factors associated with relapse risk were identified. Results At ART initiation, 162 women, median age 33 years (IQR: 30–37), median Expanded Disability Status Scale score 1.5 (IQR: 1.0–2.5) were included; 55 (34.0%) were exposed to DMT. 27 relapses were recorded (ARR (95% CI) 0.17 (0.11 to 0.26)) at 12 months pre-ART; 7 relapses and 0.17 (0.08 to 0.36) at 3 months post-ART initiation, and 16 relapses and 0.13 (0.08 to 0.23) at 9 months post-ART initiation. When stratified by ART outcomes, relapse counts in subgroups became small. Women continuing DMT at ART initiation showed a statistically non-significant increase in ARR at 3 months post-ART. Conclusions Women with RRMS in Denmark did not, on average, have increased relapse activity at 3 and 9 months post-ART initiation compared with 12 months pre-ART. Women with disease activity pre-ART initiation may have a potentially elevated relapse risk post-ART.
- Open Access
- 3 July 2025
- Published by BMJ in BMJ Neurology Open
- Vol. 7 (2) , e001092
Disease-modifying therapy during pregnancy and postpartum relapse activity in women with multiple sclerosis undergoing assisted reproductive technology treatment: a nationwide cohort study
Background: Evidence is scarce concerning the impact on postpartum relapse activity of disease-modifying therapy (DMT) use during pregnancy after assisted reproductive technology (ART) treatment. We investigated relapse activity before pregnancy, during pregnancy and 3 and 12 months postpartum overall and according to DMT exposure during pregnancy. Methods: Women with relapsing-remitting multiple sclerosis (MS) from the Danish MS Registry who gave birth after ART from 1995 to 2018 were eligible for inclusion. Annualised relapse rate (ARR) before pregnancy, during pregnancy and postpartum was evaluated using a negative binomial regression model with relapse count as the dependent variable overall and according to DMT exposure during pregnancy. Logistic regression was used to identify predictors of being relapse-free 12 months postpartum. Results: A total of 111 women, median age 32 years (IQR: 29–35), were included. Overall, ARR (95% CI) was 0.14 (0.08 to 0.24) before pregnancy, 0.13 (0.07 to 0.25) during pregnancy and 0.33 (0.17 to 0.61) 3 months postpartum; rate ratio difference between before pregnancy and postpartum was 2.42 (1.03 to 5.67), and between during pregnancy and postpartum was 2.46 (1.18 to 5.13). Age ≥35 years and no DMT exposure before pregnancy were predictors of being relapse-free 12 months postpartum. Conclusions: Relapse activity was more than two times higher 3 months postpartum than before and during pregnancy. Stratified for DMT exposure during pregnancy, rate ratios were similar and did not reach statistical significance. Postpartum relapse activity more than doubled from both low ARR (unexposed to DMT during pregnancy) and higher ARR (exposed to DMT during pregnancy) pre-pregnancy.
- 3 July 2025
- Published by BMJ in BMJ Neurology Open
- Vol. 7 (2) , e001092
Open AccessDisease-modifying therapy during pregnancy and postpartum relapse activity in women with multiple sclerosis undergoing assisted reproductive technology treatment: a nationwide cohort study
Background: Evidence is scarce concerning the impact on postpartum relapse activity of disease-modifying therapy (DMT) use during pregnancy after assisted reproductive technology (ART) treatment. We investigated relapse activity before pregnancy, during pregnancy and 3 and 12 months postpartum overall and according to DMT exposure during pregnancy. Methods: Women with relapsing-remitting multiple sclerosis (MS) from the Danish MS Registry who gave birth after ART from 1995 to 2018 were eligible for inclusion. Annualised relapse rate (ARR) before pregnancy, during pregnancy and postpartum was evaluated using a negative binomial regression model with relapse count as the dependent variable overall and according to DMT exposure during pregnancy. Logistic regression was used to identify predictors of being relapse-free 12 months postpartum. Results: A total of 111 women, median age 32 years (IQR: 29–35), were included. Overall, ARR (95% CI) was 0.14 (0.08 to 0.24) before pregnancy, 0.13 (0.07 to 0.25) during pregnancy and 0.33 (0.17 to 0.61) 3 months postpartum; rate ratio difference between before pregnancy and postpartum was 2.42 (1.03 to 5.67), and between during pregnancy and postpartum was 2.46 (1.18 to 5.13). Age ≥35 years and no DMT exposure before pregnancy were predictors of being relapse-free 12 months postpartum. Conclusions: Relapse activity was more than two times higher 3 months postpartum than before and during pregnancy. Stratified for DMT exposure during pregnancy, rate ratios were similar and did not reach statistical significance. Postpartum relapse activity more than doubled from both low ARR (unexposed to DMT during pregnancy) and higher ARR (exposed to DMT during pregnancy) pre-pregnancy.
- Open Access
- 1 October 2024
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 16, 717-732
Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study
Purpose: Understanding the long-term safety of disease-modifying therapies for multiple sclerosis (MS) in routine clinical practice can be undertaken through registry-based studies. However, variability of data quality across such sources poses the challenge of data fit for regulatory decision-making. CLARION, a non-interventional cohort safety study of cladribine tablets, combines aggregated data from MS registries/data sources, except in Germany (which utilizes primary data collection). We describe the application of key data quality indicators (DQIs) within CLARION to evaluate data quality over time, as recommended by the European Medicines Agency (EMA) guideline on registry-based studies. Methods: DQIs were defined with participating registries/sources; they were used to assess data quality according to the EMA Data Quality Framework, addressing consistency, accuracy, completeness, and study representativeness. DQIs were associated with potential remedial measures if data quality was not met. DQIs were summarized overall and for individual MS registries/data sources to November 1, 2022. Results: A total of 28 DQIs were analyzed using data from 5069 patients arising from eight MS registries/data sources and 14 countries. The Representativeness DQIs showed that 72.0% of patients were female, median age at MS diagnosis was 29.0 to 43.3 years, and 93.5% had relapsing-remitting MS. Consistency DQIs showed a total of 2899 patients had achieved at least two years of follow-up; 6.9% did not have any recorded visits during this timeframe. Discrepant values were assessed as part of Accuracy DQIs, and improvements over time were noted for recorded dates of MS onset and diagnosis. Regarding Completeness DQIs, 191/5069 (3.8%) patients were lost to follow-up. Conclusion: The application of 28 DQIs within the CLARION study has helped with understanding, not only intrinsic and question-specific determinants of data quality, but also tracking the quality of post-authorization safety data obtained from MS registries/data sources, thereby providing a foundation for the regulatory decision-making process.
- 1 October 2024
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 16, 717-732
Open AccessHarmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study
Purpose: Understanding the long-term safety of disease-modifying therapies for multiple sclerosis (MS) in routine clinical practice can be undertaken through registry-based studies. However, variability of data quality across such sources poses the challenge of data fit for regulatory decision-making. CLARION, a non-interventional cohort safety study of cladribine tablets, combines aggregated data from MS registries/data sources, except in Germany (which utilizes primary data collection). We describe the application of key data quality indicators (DQIs) within CLARION to evaluate data quality over time, as recommended by the European Medicines Agency (EMA) guideline on registry-based studies. Methods: DQIs were defined with participating registries/sources; they were used to assess data quality according to the EMA Data Quality Framework, addressing consistency, accuracy, completeness, and study representativeness. DQIs were associated with potential remedial measures if data quality was not met. DQIs were summarized overall and for individual MS registries/data sources to November 1, 2022. Results: A total of 28 DQIs were analyzed using data from 5069 patients arising from eight MS registries/data sources and 14 countries. The Representativeness DQIs showed that 72.0% of patients were female, median age at MS diagnosis was 29.0 to 43.3 years, and 93.5% had relapsing-remitting MS. Consistency DQIs showed a total of 2899 patients had achieved at least two years of follow-up; 6.9% did not have any recorded visits during this timeframe. Discrepant values were assessed as part of Accuracy DQIs, and improvements over time were noted for recorded dates of MS onset and diagnosis. Regarding Completeness DQIs, 191/5069 (3.8%) patients were lost to follow-up. Conclusion: The application of 28 DQIs within the CLARION study has helped with understanding, not only intrinsic and question-specific determinants of data quality, but also tracking the quality of post-authorization safety data obtained from MS registries/data sources, thereby providing a foundation for the regulatory decision-making process.
- Open Access
- 11 January 2024
- Published by Wiley in Journal of Pregnancy
- Vol. 2024, 1-13
Drug Utilization Studies in Pregnant Women for Newly Licensed Medicinal Products: A Contribution from IMI ConcePTION
Purpose. Studies focusing on safety outcomes typically require large populations to comprehensively characterise the patient groups exposed to the medicines under investigation. However, there is often less information for subpopulations, such as pregnant or breastfeeding women, particularly when new medicines are considered. It is important to understand what information can be obtained from drug utilization studies (DUS) involving pregnant women in the early years postmarketing to provide supportive information for safety studies. The aims of this literature review are to (1) identify and review DUS for new medicines in pregnancy and breastfeeding and (2) list and summarise key information items to be reported in a DUS for new medicines in pregnancy. Methods. To identify postmarketing DUS of new prescription medicines or enantiomers in pregnancy, a systematic literature review was undertaken in PubMed and Embase between January 2015 and June 2022. In addition, the complete database of the ENCePP EU PAS Register was systematically searched to June 2022. Results. We identified 11 published DUS on new medicines in pregnancy from the ENCePP EU PAS Register and none from other sources. No studies on breastfeeding were identified. The 11 identified publications reported the medicine’s use for the first 3 to 5 years after marketing approval. No reports assessed utilization in the first 3 years of approval. It was usual to issue interim reports annually (7 studies). All studies concerned conditions managed in ambulatory care (primary care and outpatient facilities) and included some primary care prescribing. Most ( ) only had prescribing/dispensing data available at individual level for ambulatory care; outpatient prescribing was included in three of these studies Three studies held a limited amount of in-hospital prescribing data. A DUS can confirm at an early stage whether there are sufficient exposed pregnancies in available data sources to ensure a safety study is powered to detect a difference in the prevalence of adverse pregnancy or infant outcomes or if additional data from other databases are needed. A DUS may also help address methodological considerations such as selection of comparators. DUS can be performed embedded in a DUS in the general population, in a cohort of women of childbearing age, or in a cohort of pregnant women. Conclusion. This review summarises key aspects of a DUS for new medicines in pregnancy. DUS for new medicines in pregnancy should be planned before marketing, scheduled for the first 3 to 5 years after release, with annual interim/progress reports, and reported in peer-reviewed journals. By offering detailed information on data sources, exposure timing, prevalence and location, coprescribing, comorbidities, coexposures, and demographics, a DUS will offer a firm foundation for safety studies and will help to contextualize spontaneous reporting of serious adverse events.
- 11 January 2024
- Published by Wiley in Journal of Pregnancy
- Vol. 2024, 1-13
Open AccessDrug Utilization Studies in Pregnant Women for Newly Licensed Medicinal Products: A Contribution from IMI ConcePTION
Purpose. Studies focusing on safety outcomes typically require large populations to comprehensively characterise the patient groups exposed to the medicines under investigation. However, there is often less information for subpopulations, such as pregnant or breastfeeding women, particularly when new medicines are considered. It is important to understand what information can be obtained from drug utilization studies (DUS) involving pregnant women in the early years postmarketing to provide supportive information for safety studies. The aims of this literature review are to (1) identify and review DUS for new medicines in pregnancy and breastfeeding and (2) list and summarise key information items to be reported in a DUS for new medicines in pregnancy. Methods. To identify postmarketing DUS of new prescription medicines or enantiomers in pregnancy, a systematic literature review was undertaken in PubMed and Embase between January 2015 and June 2022. In addition, the complete database of the ENCePP EU PAS Register was systematically searched to June 2022. Results. We identified 11 published DUS on new medicines in pregnancy from the ENCePP EU PAS Register and none from other sources. No studies on breastfeeding were identified. The 11 identified publications reported the medicine’s use for the first 3 to 5 years after marketing approval. No reports assessed utilization in the first 3 years of approval. It was usual to issue interim reports annually (7 studies). All studies concerned conditions managed in ambulatory care (primary care and outpatient facilities) and included some primary care prescribing. Most ( ) only had prescribing/dispensing data available at individual level for ambulatory care; outpatient prescribing was included in three of these studies Three studies held a limited amount of in-hospital prescribing data. A DUS can confirm at an early stage whether there are sufficient exposed pregnancies in available data sources to ensure a safety study is powered to detect a difference in the prevalence of adverse pregnancy or infant outcomes or if additional data from other databases are needed. A DUS may also help address methodological considerations such as selection of comparators. DUS can be performed embedded in a DUS in the general population, in a cohort of women of childbearing age, or in a cohort of pregnant women. Conclusion. This review summarises key aspects of a DUS for new medicines in pregnancy. DUS for new medicines in pregnancy should be planned before marketing, scheduled for the first 3 to 5 years after release, with annual interim/progress reports, and reported in peer-reviewed journals. By offering detailed information on data sources, exposure timing, prevalence and location, coprescribing, comorbidities, coexposures, and demographics, a DUS will offer a firm foundation for safety studies and will help to contextualize spontaneous reporting of serious adverse events.
- Open Access
- 9 August 2023
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 32 (12) , 1421-1430
Risk of cancer with immunosuppressants compared to immunomodulators in multiple sclerosis: A nested case–control study within the French nationwide claims database
Purpose: The objective was to compare the risk of malignancies in real‐world settings between exclusive immunosuppressant (IS) and immunomodulator (IM) use in multiple sclerosis (MS).Methods: A nested case–control study was designed within a new‐user cohort of all patients with MS who initiated a first IM or IS between 2008 and 2014, and without cancer history, using the information of the SNDS nationwide French claims database. Incident cancer cases were matched with up to six controls on year of birth, sex, initiation date, and disease risk score of cancer. A conditional logistic regression (odds ratio [95% confidence interval]) was used to compare exclusive IS versus IM use during follow‐up and according to three use durations.Results: From 28 720 newly treated patients with MS, 407 incident cancers were observed during the follow‐up with 2324 matched controls. A significant increase in cancer risk was observed for IS compared with IM (1.36 [1.05, 1.77]), with similar increases for the first 2 years of use but not for ≥2 years (1.06 [0.65, 1.75]). Similar increase was also observed for IS with indications other than MS (1.37 [1.04, 1.81]) but not for IS indicated only in MS (1.03 [0.45, 2.34]).Conclusions: Compared with IM, a 37% increase in cancer risk was observed for IS with indications other than MS and used for a short duration (≤2 years) but not for IS indicated only in MS. The absence of risk for prolonged exposure of IS with indications other than MS is not in favor of a causal relation with these drugs.
- 9 August 2023
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 32 (12) , 1421-1430
Open AccessRisk of cancer with immunosuppressants compared to immunomodulators in multiple sclerosis: A nested case–control study within the French nationwide claims database
Purpose: The objective was to compare the risk of malignancies in real‐world settings between exclusive immunosuppressant (IS) and immunomodulator (IM) use in multiple sclerosis (MS).Methods: A nested case–control study was designed within a new‐user cohort of all patients with MS who initiated a first IM or IS between 2008 and 2014, and without cancer history, using the information of the SNDS nationwide French claims database. Incident cancer cases were matched with up to six controls on year of birth, sex, initiation date, and disease risk score of cancer. A conditional logistic regression (odds ratio [95% confidence interval]) was used to compare exclusive IS versus IM use during follow‐up and according to three use durations.Results: From 28 720 newly treated patients with MS, 407 incident cancers were observed during the follow‐up with 2324 matched controls. A significant increase in cancer risk was observed for IS compared with IM (1.36 [1.05, 1.77]), with similar increases for the first 2 years of use but not for ≥2 years (1.06 [0.65, 1.75]). Similar increase was also observed for IS with indications other than MS (1.37 [1.04, 1.81]) but not for IS indicated only in MS (1.03 [0.45, 2.34]).Conclusions: Compared with IM, a 37% increase in cancer risk was observed for IS with indications other than MS and used for a short duration (≤2 years) but not for IS indicated only in MS. The absence of risk for prolonged exposure of IS with indications other than MS is not in favor of a causal relation with these drugs.
- Open Access
- 1 January 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 37, 101591
No Effect on Infant Birth Weight and Head Circumference After Exposure to Interferon Beta Prior to Or During Pregnancy: A Register-Based Cohort Study in Finland and Sweden Among Women with Multiple Sclerosis
- 1 January 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 37, 101591
Open AccessNo Effect on Infant Birth Weight and Head Circumference After Exposure to Interferon Beta Prior to Or During Pregnancy: A Register-Based Cohort Study in Finland and Sweden Among Women with Multiple Sclerosis
- Open Access
- 14 June 2019
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 145 (8) , 2105-2114
Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies
Most metastatic colorectal cancer (mCRC) patients are elderly. This systematic review identifies and describes observational studies evaluating the influence of age on first-line treatment effectiveness in real-world practice.
- 14 June 2019
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 145 (8) , 2105-2114
Open AccessEffect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies
Most metastatic colorectal cancer (mCRC) patients are elderly. This systematic review identifies and describes observational studies evaluating the influence of age on first-line treatment effectiveness in real-world practice.